#AIDS2020VIRTUAL: Access to Covid-19 vaccine should be a public good
Scientists taking part in the 23rd International Aids Conference online are more optimistic about a Covid-19 vaccine than they were about the HIV vaccine.
HIV Vaccine Trials Network executive director Dr Jim Kublin said there is a good reason to be optimistic.
“I think that type of neutralisation of the virus that was observed, with Zika and Ebola and some of these other viruses that we’ve been able to turn around vaccine development against very quickly,” he told delegates attending the virtual conference.
Kublin was part of a panel that focused on the current state of the Covid-19 across the globe. It included experts such as Wits Reproductive Health and HIV Institute founder Dr Helen Rees, AIDProject group co-chair Reverend Rob Newells and Vaccine Advocacy Resource Group member Dr Morenike Ukpong.
Access to Covid-19 vaccine should be a public good
Rees said that should an effective vaccine be found everyone should have access to the new treatment.
“The first thing is that that these vaccines must be regarded as a global public good, that they’re really in terms of equity and rights based arguments that they must be regarded as vaccines that have to be made equitably available all over the world,” she said.
But Rees also warned that the vaccine may not be immediately available for everyone.
“We also know that even if we have a successful vaccine today you know results that come out next year there by the end of 2021 (and) we won’t have enough vaccine even if there is one, for the whole world,” she explained.
She added that those who are working as nurses, doctors and other patient-facing positions should get access to a vaccine first.
“One group that’s seen as a major priority are healthcare workers and frontline workers. Because if we can’t and particularly if you take at the African region. You can’t protect your health care workers and they fall down… not only for COVID, they fall down for HIV for TB for every non-communicable.”
Covid 19 PrEP on the table
Rees said the development of pre-exposure prophylaxis (PrEP) learned during the response to HIV helped in the struggle to cope with the Covid-19 pandemic.
This was lent credence by an earlier call by New York based PrEP4All Collaboration which approached the World Health Organisation to investigate the development of a PrEP as part of Covid-19 prevention strategy.
“What’s been happening since extensive work getting on, and people are looking at the two things,” said Rees.
“First of all, what’s called repurposing of existing drugs, and these could be drugs that are licenced drugs that are unlicensed and sitting on a shelf somewhere and so on drugs that might have been tried in a clinical trial and not successful but existing drugs, because that’s much quicker,” she explained.
She believes artificial intelligence and computer power which is being harnessed to investigate the effect of HIV drugs on other diseases will be crucial.
“We looked at some of the antibody antivirals we’re familiar with in HIV, but we’re (also) looking at antivirals for hepatitis C and so on so there’s a lot of the antivirals, the malaria drugs.”
Rees says that scientists are looking at drugs that are effective in supporting the immune system and those that act directly on the Covid-19 virus as well.
“The urgency of those trials is the same as the urgency for vaccines,” she said. – Health-e News
Author
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
You must include all of the links from our story, including our newsletter sign up link.
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
#AIDS2020VIRTUAL: Access to Covid-19 vaccine should be a public good
by Nelisiwe Msomi, Health-e News
July 10, 2020